{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:15:37Z","timestamp":1779164137590,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jbiotec.2026.02.007","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:02:20Z","timestamp":1771488140000},"page":"16-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The complex patent situation regarding antibody Fc engineering"],"prefix":"10.1016","volume":"413","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9565-9857","authenticated-orcid":false,"given":"Ulrich","family":"Storz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbiotec.2026.02.007_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates","volume":"39","author":"Aoyama","year":"2022","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.02.007_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/antib7010006","article-title":"In-depth comparison of lysine-based antibody-drug conjugates prepared on solid support versus in solution","volume":"7","author":"Arlotta","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.jbiotec.2026.02.007_bib3","unstructured":"Can be downloaded at \u3008http:\/\/planetorbitrap.com\/download.php?filename=52d9bccd14347.pdf\u3009."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.02.007_bib4","first-page":"127","article-title":"Immunoconjugates containing novel maytansinoids: promising anticancer drugs","volume":"52","author":"Chari","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbiotec.2026.02.007_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41587-022-01282-6","article-title":"First soluble TCR therapy opens \u2018new universe\u2019 of cancer targets","volume":"40","author":"Dolgin","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.jbiotec.2026.02.007_bib6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbiotec.2026.02.007_bib7","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbiotec.2026.02.007_bib8","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.4049\/jimmunol.147.8.2657","article-title":"Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG","volume":"147","author":"Lund","year":"1991","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.jbiotec.2026.02.007_bib9","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int Immunol."},{"key":"10.1016\/j.jbiotec.2026.02.007_bib10","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc\u03b3R affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbiotec.2026.02.007_bib11","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jbiotec.2026.02.007_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0003-9861(86)90031-7","article-title":"Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose","volume":"249","author":"Ripka","year":"1986","journal-title":"Arch. Biochem Biophys."},{"issue":"6","key":"10.1016\/j.jbiotec.2026.02.007_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/19420862.2015.1082019","article-title":"Antibody-drug conjugates: intellectual property considerations","volume":"7","author":"Storz","year":"2015","journal-title":"MAbs"},{"issue":"1-2","key":"10.1016\/j.jbiotec.2026.02.007_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/HAB-160300","article-title":"Of patents and patent disputes: the TNF\u03b1 patent files. Part 1: humira","volume":"25","author":"Storz","year":"2017","journal-title":"Hum. Antibodies"},{"issue":"2","key":"10.1016\/j.jbiotec.2026.02.007_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/HAB-240006","article-title":"The rebirth of epitope-based patent claims","volume":"32","author":"Storz","year":"2024","journal-title":"Hum. Antibodies"},{"issue":"5","key":"10.1016\/j.jbiotec.2026.02.007_bib16","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1021\/acsomega.9b00430","article-title":"Study on the heterogeneity of T-DM1 and the analysis of the unconjugated linker structure under a stable conjugation process","volume":"4","author":"Wu","year":"2019","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.jbiotec.2026.02.007_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/antib13040099","article-title":"50 years of antibody numbering schemes: a statistical and structural evaluation reveals key differences and limitations","volume":"13","author":"Zhu","year":"2024","journal-title":"Antibodies"}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165626000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165626000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:29:52Z","timestamp":1773221392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168165626000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":17,"alternative-id":["S0168165626000398"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2026.02.007","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The complex patent situation regarding antibody Fc engineering","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2026.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}